Could a diabetes drug help kidney patients lose weight?
NCT ID NCT07176663
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the safety and effectiveness of tirzepatide (Spartina) for weight loss in 15 adults with chronic kidney failure who also have diabetes or obesity. Participants receive weekly injections for three months. The goal is to see if this drug can help manage weight and blood sugar without the risks of other treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tirzepatide (Spartina)
What this could lead to
If it works, this could point toward a way to help people with kidney failure lose weight and manage diabetes without the side effects of other drugs.
What could go wrong
This is a very small, early study with only 15 people, so results may not apply to everyone. The drug may not work as hoped or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Nooshin Dalili
Tehran, 1666663421, Iran